FDA
Novo Nordisk Settles Two Ozempic and Wegovy Copycat Lawsuits
Novo Nordisk announced last month that it settled two lawsuits against two businesses – Cosmetic Laser Professional Med Spa and Nuvida RX Weight Loss – who claimed to offer compounded versions of its Ozempic and Wegovy drugs. The two businesses, based in Florida, are permanently banned from claiming that their compounded drugs are approved Food…
Read MoreFDA and NABP Partnership: Information-Sharing for Drug Compounding
The Food and Drug Administration (FDA) recently announced that it awarded a cooperative grant to the National Association of Boards of Pharmacy (NABP) to create an information-sharing data system to improve the information available to state regulators and the FDA about state-licensed pharmacies that engage in interstate distribution of compounded drugs. The new data system…
Read MoreFDA and FTC Issue Joint Warning to Pharmacy Selling Unapproved Products containing CBD
Earlier this month, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a warning letter to Rooted Apothecary LLC (Rooted Apothecary) for illegally marketing and selling unapproved cannabidiol (CBD) products with unsubstantiated claims that these products treat teething and ear pain in infants, autism, attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s and Alzheimer’s…
Read MoreNew Colorado Law Allows Doctors to Recommend Medical Marijuana for Disabling Medical Conditions
Colorado lawmakers passed Senate Bill 19-013 (Concerning the Conditions for Medical Marijuana Use For Disabling Conditions, and, in connection therewith, Adding a Condition for Which a Physician Could Prescribe an Opioid to the List of Disabling Medical Conditions for Medical Marijuana Use) in May 2019 and it took effect August 2, 2019. Senate Bill 19-013 allows doctors…
Read MoreNABP Statement on Prescription Drug Importation Proposals
Last month the National Association of Boards of Pharmacy (NABP) released a ‘Statement on Prescription Drug Importation Proposals‘ reiterating its stance that prescription drug importation is not a viable solution to addressing high prescription drug costs. The NABP statement is in response to recent policymaker proposals seeking to allow (1) the importation of prescription drugs…
Read MoreFDA Cracks Down on Dietary Supplements
Yesterday, Dr. Scott Gottlieb, the Food and Drug Administration’s Commissioner, announced a new plan to crack down on dietary supplement makers who claim their products can prevent, treat or cure certain diseases. Gottlieb revealed the FDA sent twelve warning letters and five advisory letters to companies whose products are being illegally marketed as unapproved new drugs…
Read More